A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

was significantly associated with survival by either univariate (TS hazard ratio (HR) = 0.94, 95% CI 0.76–1.18 and P = 0.6 and p53 HR = 0.98, 95% CI 0.78–1.23 and P = 0.9) or multivariate analyses (TS HR = 0.99, 95% CI 0.79–1.25 and P = 0.9 and p53 HR = 0.98, 95% CI 0.78–1.23 and P = 0.8). Conclusions: Neither TS nor p53 expression has significant prognostic value in the adjuvant setting of CRC.